GC Biopharma said Friday that it has been selected for the Ministry of Health and Welfare’s “Advanced Bio Convergence Talent Development Project” and will jointly develop the world’s first AI-based clinical decision support system (CDSS) for predicting hemophilic arthropathy.
For the project, the company will collaborate with the Korea Hemophilia Foundation, Seoul National University College of Pharmacy, and Samsung Medical Center.
GC Biopharma headquarters in Yongin, Gyeonggi Province (Courtesy of GC Biopharma)
Hemophilic arthropathy, caused by recurrent bleeding into the joints, is known to affect about 70 percent of patients with severe hemophilia in Korea. Repeated bleeding damages the synovium, cartilage, and subchondral bone, leading to chronic pain and reduced mobility that significantly impair patients’ quality of life.
However, standardized models capable of quantitatively predicting the long-term risk of joint damage have remained limited.
The project will utilize 30 years of accumulated real-world data from Korean hemophilia patients along with approximately 3,000 X-ray images. Using AI-based machine-learning technologies, GC Biopharma plans to develop a predictive model that analyzes a range of clinical variables, including patient age, prophylactic treatment history, and existing levels of joint damage, to predict future progression of joint deterioration.
The company will also develop an AI-powered deep-learning imaging analysis tool that interprets X-ray images to assist clinicians in diagnosing hemophilic arthropathy.
Through the CDSS, healthcare professionals will be able to predict patients’ joint health outcomes from 5 to 20 years into the future based on current clinical status and degree of joint damage. The system will also enable comparative analysis of patient prognoses depending on whether preventive treatment is administered.
GC Biopharma said it expects the platform to support personalized treatment strategies and facilitate earlier intervention for hemophilia patients.
The company plans to complete development of the arthropathy prediction model by the end of this year, followed next year by development of the X-ray interpretation technology and a CDSS prototype. It aims to finalize the full system by 2028 while preparing patent applications and regulatory approval submissions to the Ministry of Food and Drug Safety.
“Using AI technology, we expect to predict joint damage in hemophilia patients at an earlier stage and support personalized treatment decisions,” said Choi Bong-gyu, director of GC Biopharma's AI & Data Science (AID). “Ultimately, we hope to reduce the burden of joint surgeries and hospitalizations while improving patients’ quality of life.”
GC Biopharma plans to present interim findings from the hemophilic arthropathy prediction model development at a hemophilia symposium hosted by the company on June 12 under the theme, “Developing a Predictive Model for Arthropathy Risk in Korean Patients with Hemophilia.”
Lee Han-soo
댓글
0